GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » Cyclically Adjusted PB Ratio

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.00 (As of Apr. 30, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-04-30), Cyclacel Pharmaceuticals's current share price is $1.36. Cyclacel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $1,202.68. Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Cyclacel Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.50. The lowest was 0.01. And the median was 0.04.

CYCC's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.74
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cyclacel Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $0.573. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1,202.68 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.03 0.02 0.01 -

Cyclacel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - 0.01 - -

Competitive Comparison of Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.36/1202.68
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclacel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Cyclacel Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.573/129.4194*129.4194
=0.573

Current CPI (Dec. 2023) = 129.4194.

Cyclacel Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 4,540.909 99.695 5,894.826
201406 4,696.667 100.560 6,044.579
201409 3,911.587 100.428 5,040.788
201412 3,367.702 99.070 4,399.387
201503 2,830.262 99.621 3,676.840
201506 2,523.560 100.684 3,243.792
201509 2,240.664 100.392 2,888.545
201512 1,906.377 99.792 2,472.354
201603 1,609.211 100.470 2,072.880
201606 1,313.573 101.688 1,671.797
201609 1,195.554 101.861 1,519.010
201612 1,005.849 101.863 1,277.959
201703 900.140 102.862 1,132.540
201706 786.216 103.349 984.543
201709 601.641 104.136 747.718
201712 544.286 104.011 677.247
201803 510.003 105.290 626.884
201806 465.716 106.317 566.916
201809 415.054 106.507 504.344
201812 366.587 105.998 447.589
201903 306.210 107.251 369.504
201906 274.394 108.070 328.602
201909 241.619 108.329 288.658
201912 204.029 108.420 243.546
202003 181.249 108.902 215.398
202006 81.963 108.767 97.526
202009 75.363 109.815 88.817
202012 79.861 109.897 94.048
202103 78.051 111.754 90.389
202106 70.200 114.631 79.256
202109 63.327 115.734 70.815
202112 56.578 117.630 62.249
202203 50.149 121.301 53.505
202206 39.920 125.017 41.326
202209 31.774 125.227 32.838
202212 24.443 125.222 25.262
202303 17.516 127.348 17.801
202306 11.426 128.729 11.487
202309 5.098 129.860 5.081
202312 0.573 129.419 0.573

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cyclacel Pharmaceuticals  (NAS:CYCC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Executives
Spiro Rombotis director, officer: President & C.E.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron director, officer: E.V.P., Finance & C.O.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson director 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker director 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker director C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum officer: Chief Medical Officer 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd. 10 percent owner 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart 10 percent owner P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems director C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Headlines